Coherus BioSciences Inc., stopped earlier this month in its efforts to offer a lower-cost version of a drug for cancer chemotherapy patients, will lay off 30 percent of its workforce.
The Redwood City company (NASDAQ: CHRS) said it cut 51 jobs after the Food and Drug Administration asked it to reanalyze some data from clinical trials and provide more information about manufacturing. Coherus leaders had hoped to win FDA approval this month of the drug, its version of Amgen Inc.'s Neulasta, and hit…
Coherus BioSciences Inc., stopped earlier this month in its efforts to offer a lower-cost version of a drug for cancer chemotherapy patients, will lay off 30 percent of its workforce.
The Redwood City company (NASDAQ: CHRS) said it cut 51 jobs after the Food and Drug Administration asked it to reanalyze some data from clinical trials and provide more information about manufacturing. Coherus leaders had hoped to win FDA approval this month of the drug, its version of Amgen Inc.'s Neulasta, and hit…